“So, we're comfortable we could still achieve the mid-single-digit growth even after the diabetes separation.”

In context

“ure that opportunity. So sure, we'll be working on it. So look, we've tried to give a guidance. That's all in, and we'll work from there. You also had a part of the question on '27. Sorry, I wanted to address your -- the ’27 part of the question. Look, as Geoff mentioned, the growth is not a one-off thing in '25 or in Q4 '25. It's going to carry into '26. And some of the new products that are carrying this are going to carry us well into '27. So, Geoff mentioned CAS and Ardian and Tibial that will start having a small impact towards the end of '26 and we'll carry into '27. So first, we expect to continue to have good growth into '27, and that's regardless of the separation of the diabetes business. Just to give you some clarity on that. Diabetes drives about 40 basis points of our growth. So, we're comfortable we could still achieve the mid-single-digit growth even after the diabetes separation. We'll continue to drive the cost-out initiatives, as I mentioned earlier, FX should start turning into a small headwind towards the end of '26 and into 27. And the last item I wanted to mention is, we'll probably talk about it more in detail on the rest of the conversation. But the deal that we're -- the structure that we're taking on the diabetes deal actually provides us the opportunity to retire some shares. So, this will be immediately accretive to our EPS and help strengthen the construction to get back to high single-digit growth into '27. Geoff Martha: And just one clarification on FX -- on the FX, it flips to a tailwind. Thierry Pieton: Did I say headwind? Sorry. tailwind. Sorry. Geoff Martha: You got tax on your mind, that's headwind. But FX flips to a tailwind. Ryan Weispfenning”